Invitae Hereditary Breast Cancer Guidelines-Based Panel
Use
This panel analyzes genes that are associated with predisposition to adult-onset breast cancer and provides medically actionable, evidence-based management and risk-reduction options. It guides cancer screening and risk-reduction measures, defining the age and intervals of screenings, preventive options, and the risk for subsequent primary cancers. Such measures may prevent cancer or lead to earlier diagnosis, thus increasing the chances of successful treatment and survival. The test covers a broad panel of genes to efficiently evaluate several potential genetic indicators based on a single clinical indication.
Special Instructions
Not provided.
Limitations
The assay achieves >99% analytical sensitivity and specificity for detecting most variants but may have marginally reduced sensitivity for large insertions and deletions. Some single-exon events might not be analyzed due to data quality issues. The assay is not designed for detecting somatic mutations in tumor tissue.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant